[ad_1]
Workers demonstrate how to transport large quantities of vaccines.
The difficult crossword of the invasion of the coronavirus and the opening of the economy is called upon to be managed, in the run-up to Christmas, by European governments, and the coronavirus continues to harvest.
In this climate, states and governments eagerly await good news from the European Medicines Agency (Core) on the vaccines in question, despite objections to the fact that they have been developed in record time, which has not happened. never again on such a large scale.
The EMA, according to the Financial Times in its report, will make decisions in December on the vaccine of the Pfizer / Biontech companies, but also the one developed by the Moderna company.
These developments come in the shadow of the AstraZeneca case, where a series of errors and omissions shook regulators’ confidence in the company, resulting in the vaccine being retested around the world.
German officials, according to the FT, said in the past two days that preparations have been made to start the first vaccinations next month, as soon as the European regulatory authorities give the “green light.”
“We expect the Pfizer / Biontech vaccine to be approved in mid-December,” said German Health Minister Jens Spann.
The European Medicines Agency, which issues licenses for the entire EU, will decide in the coming weeks and approve the Moderna vaccine for one.
It should be noted that the European Union has signed agreements with six companies that manufacture the coronavirus vaccine, having already given several million in advances.
However, there are several hurdles that need to be overcome and the timeline could, in the end, go far behind, say people with knowledge of the procedures within Coreper.
The regulator has a difficult task balancing the huge need for public health and proper vaccine testing, and the political pressure is enormous, especially as the US and UK are apparently expected to initiate proceedings. vaccination well in advance. The EMA, however, claims that it has not received political pressure to take the necessary measures quickly.
Today, however, the leading US epidemiologist said the vaccine would be available starting in December for people at higher risk of developing a severe form of the disease. People should be aware that “the development process of this vaccine has been carried out with scientific rigor. “Security has not been compromised,” he said.
